News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Pernix Therapeutics, Inc. Reports Second Quarter 2012 Financial Results
August 14, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
THE WOODLANDS, Texas--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NYSE MKT: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and six months ended June 30, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Psychedelics
J&J sees Spravato sales surge as psychedelic competitors loom
July 16, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
July 16, 2026
·
6 min read
·
Angela Gabriel
Manufacturing
Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chain
July 15, 2026
·
1 min read
·
Gabrielle Masson
Antibody-drug conjugate
Pfizer scraps Seagen-developed ADC for solid tumors
July 15, 2026
·
1 min read
·
Gabrielle Masson